Patient prognosis remains favorable as long as the tumor maintains its capacity to respond adequately to radioactive iodine (RAI) 131 I therapy.1 Iodine plays a critical role in the biosynthesis of thyroid hormones and is actively transported into the follicular cells of the thyroid via the sodium–iodide symporter (NIS) on the plasma membrane. Here, SLC5A5 is linked to neoplasm.